Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma

Nazli Dizman; Matthew Austin; Bryden Considine; Shlomit Jessel; David Schoenfeld; Man Yee Merl; Michael Hurwitz; Mario Sznol; Harriet Kluger

doi:10.1016/j.clgc.2023.01.002

Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma

Clin Genitourin Cancer. 2023 Apr;21(2):221-229. doi: 10.1016/j.clgc.2023.01.002. Epub 2023 Jan 12.

Authors

Nazli Dizman¹, Matthew Austin², Bryden Considine², Shlomit Jessel², David Schoenfeld², Man Yee Merl³, Michael Hurwitz², Mario Sznol², Harriet Kluger⁴

Affiliations

¹ Department of Internal Medicine, Yale School of Medicine, Yale New Haven Hospital, New Haven, CT.
² Department of Medical Oncology, Yale School of Medicine, Smilow Cancer Center, New Haven, CT.
³ Department of Pharmacy, Section of Oncology, Yale New Haven Hospital, New Haven, CT.
⁴ Department of Medical Oncology, Yale School of Medicine, Smilow Cancer Center, New Haven, CT. Electronic address: harriet.kluger@yale.edu.

PMID: 36681606
DOI: 10.1016/j.clgc.2023.01.002

Abstract

Introduction: Combination immune checkpoint inhibitors (ICI) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-R-TKI), including pembrolizumab/axitinib, are approved for first-line treatment of metastatic renal cell carcinoma (mRCC). Pembrolizumab/axitinib is associated with superior progression free survival (PFS), objective response rate (ORR), and overall survival over sunitinib. However, to date, the activity and safety of pembrolizumab/axitinib in later lines of therapy has not been reported.

Materials and methods: Clinical data of consecutive patients receiving pembrolizumab/axitinib in the second-line or beyond for mRCC at Yale-New Haven Hospital were retrospectively collected. Best objective response was assessed using RECIST 1.1 criteria. Kaplan-Meier function was used to analyze survival.

Results: Thirty-eight patients were included. Median age was 64, 92.1% had clear cell mRCC, 18.4% had sarcomatoid dedifferentiation; 94.7% had prior ICI and 39.5% had prior VEGF-R-TKI. Pembrolizumab/axitinib was administered as second-line therapy in 21 (55.5%) patients, third-line in 5 (13.2%) and beyond in 12 (30.2%). Adverse events (AEs) occurred in 86.8% of patients. Grade 3-4 AEs attributed to pembrolizumab and axitinib were seen in 18.4% and 6.4% of patients, respectively. No grade 5 AEs occurred. At a median follow up of 17.1 months, median PFS was 9.7 months (95% CI, 4.1-15.3). Amongst 36 response evaluable patients, the ORR was 25.0% (all partial) and disease control rate (including stable disease for at least 6 months) was 66.6%. The most frequent treatment sequence was first-line nivolumab/ipilimumab followed by second-line pembrolizumab/axitinib (n = 17, 44.7%); among this cohort, median PFS with pembrolizumab/axitinib was 11.1 (95% CI, 8.4-13.7) months, with an ORR of 31.4%.

Conclusion: Combination pembrolizumab/axitinib among previously treated mRCC patients has activity, with AE rates comparable to those reported in the first line. Prospective studies evaluating ICI-VEGF-R-TKI combinations beyond first-line are warranted to identify the most beneficial treatment sequencing in mRCC.

Keywords: Axitinib; Immunotherapy; Metastatic renal cell carcinoma; Pembrolizumab; Renal cell carcinoma.

MeSH terms

Axitinib
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / pathology
Prospective Studies
Retrospective Studies
Vascular Endothelial Growth Factor A

Substances

Axitinib
pembrolizumab
Vascular Endothelial Growth Factor A